Insulin, insulin analogues and cancer: No cause for panic

International Journal of Clinical Practice

Volumn 64, Issue 5, 2010, Pages 525-527

  Thomson, G A ^a,b  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^b SHERWOOD FOREST HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN RECEPTOR; SOMATOMEDIN C RECEPTOR;

CANCER RISK; CELL GROWTH; EDITORIAL; HYPERINSULINEMIA; MITOGENESIS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PANIC; PRIORITY JOURNAL;

DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; NEOPLASMS; RECEPTOR, IGF TYPE 1;

EID: 77949395116     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02365.x     Document Type: Editorial

References (15)

1. Hemkens LG, Grouven U, Bender R et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732-44.
2. Smith U, Gale EAM. Does diabetes therapy influence the risk of cancer? Diabetologia 2009; 52: 1699-708.
3. Polednak AP. Trends in incidence rates for obesity-associated cancers in the US. Cancer Detect Prev 2003; 27: 415-21.
4. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-38.
5. Volkers N. Diabetes and cancer: scientists search for a possible link. J Natl Cancer Inst 2000; 92: 192-4.
6. Cancer reform strategy. http://www.dh.gov.uk/dr-consum-dh/groups/dh- digitalassets/documents/digitalasset/dh-081007.pdf (accessed 21 February 2010).
7. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-8.
8. Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-77.
9. Govindarajan R, Ratnasinghe L, Simmons DL et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007; 25: 1476-81.
10. Pollak M, Russell-Jones D. Insulin analogues and cancer risk: cause for concern or cause célèbre? Int J Clin Pract 2010; 64: 628-36.
11. Garg SK, Hirsch IB, Skyler JS. Insulin glargine and cancer - an unsubstantiated allegation. Diab Technol Ther 2009; 11: 473-6.
12. Owens DR, Rosenstock J, Bolli GB. Insulin glargine and cancer: cause and effect unproven. Pract Diab Int 2009; 26: 256-7.
13. Craig R., Thomson GA. Where now for insulin glargine - a time for pragmatic medicine? Int J Clin Pract 2009; 63: 1413-5.
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
15. Akalin S, Berntorp K, Ceriello A et al. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control. Int J Clin Pract 2009; 63: 1421-5.